Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Michael Bitzer

Current Position: Vice Director, Head of Gastrointestinal Oncology and Molecular Tumor Board

University of Tübingen

Germany

Research Interests

Explore related searches

Professors in Germany

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Collaborators (8)

Gunnar Folprecht

Unit Chair Medical Oncology

University Hospital Carl Gustav Carus

GERMANY

View details

Fabian Finkelmeier

University Hospital Frankfurt

GERMANY

View details

Florian Dr. Reiter

GERMANY

View details

Malte Bongers

University Hospital Tübingen

GERMANY

View details

Silvio Nadalin

University of Tübingen

GERMANY

View details

Raphael Mohr

Charité - Universitätsmedizin Berlin

GERMANY

View details

Peter Horak

Deputy Head of Department

UniversitätsKlinikum Heidelberg

GERMANY

View details

Markus Diefenhardt

M.D

Klinikum der Johann Wolfgang Goethe-Universität Frankfurt

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Bitzer

Research Interests

Explore related searches

Articles (20)

Liver transplantation for refractory portal hypertension syndrome due to intrahepatic arterioportal shunts after treatment of primary hepatic choriocarcinoma: A case report

First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial.

Personalized signaling pathway analysis of gastrointestinal tumors for patient stratification and drug target evaluation using clinically derived core biopsies.

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology.

Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab.

17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome—a case for universal genetic testing?

Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial

Lenvatinib after progression on pemigatinib and futibatinib in FGFR2 fusion-positive biliary tract cancer with an acquired kinase point mutation.

B7-H3: a consistent marker in metastatic colorectal cancer with potential for targeted treatment.

Rectal stenosis after immunotherapy in a mismatch repair deficient rectal cancer. Case report and review of literature

Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps

Leitlinienreport der S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms und biliärer Karzinome“.

S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Kurzversion.

S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion.

Retrieval Augmented Therapy Suggestion for Molecular Tumor Boards: Algorithmic Development and Validation Study

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Kurzversion.

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion.

Adenosine Receptor 3 in Liver Cancer: Expression Variability, Epigenetic Modulation, and Enhanced Histone Deacetylase Inhibitor Effects.

The molecular interaction pattern of lenvatinib enables inhibition of wild-type or kinase-mutated FGFR2-driven cholangiocarcinoma.

Collaborators (8)

Gunnar Folprecht

Fabian Finkelmeier

Florian Dr. Reiter

Malte Bongers

Silvio Nadalin

Raphael Mohr

Peter Horak

Markus Diefenhardt

Make your next move.